Companies That Have Just Registered:
Welcome to the 8th Dermatology Drug Development Summit
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
Johnson & Johnson’s $2.1bn acquisition of bispecific biotechs and Eli Lilly’s IL-13 inhibitor approval for Atopic Dermatitis underscores the fierce race to bring best-in-class therapies for immuno-inflammatory skin diseases to market.
As dermatology attracts a major wave of investment, large unmet need and disease heterogeneity discoveries make Galderma’s late-stage clinical results powerful and justify Incyte’s strategic prioritization of dermatology programs.
The 8th Dermatology Drug Development Summit is the pivotal event for advancing immuno-inflammatory drug pipelines and connecting prominent industry stakeholders.
Featuring late-breaking clinical data, immersive workshops on Hidradenitis Suppurativa, JAK inhibitors and Indication Expansion, along with specialized tracks designed for Discovery & Translational and Clinical & Commercialization experts. Attendees will gain the insights needed to turn cutting-edge R&D into transformative therapies.
This November, join 130+ biopharma and investment experts from leading organizations like Johnson & Johnson, AbbVie, Alys Pharmaceuticals, Incyte, Sanofi and LEO Pharma for three days of networking and discussing the latest dermatology innovations, like targeting OX-40, oral mAbs, siRNA and more!
Whether you're a C-Level executive or advancing drug programs, this is your opportunity to shape the future of dermatology treatments and improve patient outcomes!
Don’t miss your opportunity to position your dermatology portfolio to address unmet need, with superior and long-lasting efficacy for patients this November!